Particularly, various key regulators such as HOXB13, FOXM1, or FOXA1, have been found to recruit AR or its variants to specific promoters, to sustaining cell growth and promoting progression of PRAD even in the presence of enzalutamide (Ketola et al., 2017; Song et al., 2019). Here, AR is linked to prostate adenocarcinoma.